ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 2, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 2, 2010
News
Week of Nov. 29, 2010: Company and People Notes: Lonza Forms Agreements with Two Partners; Covance Makes Executive Appointments; and More.
Lonza Forms Agreements with Two Partners; Covance Makes Executive Appointments; and More.
Genzyme Meets Consent Decree Deadline
By Erik Greb
Genzyme (Cambridge, MA) officially ended fill?finish operations at its Allston Landing, Massachusetts, plant for products sold in the United States, thereby fulfilling a requirement of a US Food and Drug Administration consent decree.
GSK Plans UK-Based R&D and Manufacturing Investment
By Patricia Van Arnum
GlaxoSmithKline (GKS, London) outlined a plan to invest EUR 500 million ($649 million) in research and development (R&D) and related manufacturing in the United Kingdom conditioned on the successful implementation of a so-called "patent box" measure by the UK government.
Survey Offers Mixed Results of FDA's Performance
By Patricia Van Arnum
PricewaterhouseCoopers (PwC) released the results of a survey that analyzed the relationship of life-science companies with the US Food and Drug Administration and their views of the agency.
Regulatory Roundup: EMA Publishes New Transparency Policy, Releases Guideline for Biosimilar mAbs.
EMA Publishes New Transparency Policy, Releases Guideline for Biosimilar mAbs.
FDA Issues New Guidance for Industry on ANDAs: Impurities in Drug Products
By Angie Drakulich
The US Food and Drug Administration issued late last week a new guidance for industry on impurities in drug products.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here